Current Status and Future Potential of Somatic Mutation Testing from Circulating Free DNA in Patients with Solid Tumours. Aung K, Board R, Ellison G, Donald E, Ward T, Clack G, Ranson M, Hughes A, Newman W, Dive C. The HUGO J (In press)
Optimization of circulating biomarkers of obatoclax-induced cell death in patients with small cell lung cancer. Dean EJ, Cummings J, Roulston A, Berger M, Ranson M, Blackhall F, Dive C. Neoplasia. 2011 (4):339-47.
Assessment of circulating biomarkers for potential pharmacodynamic utility in patients with lymphoma. Greystoke A, O'Connor JP, Linton K, Taylor MB, Cummings J, Ward T, Maders F, Hughes A, Ranson M, Illidge TM, Radford J, Dive C. Br J Cancer, 104:719-25 (2011).
Increased Sensitivity of Human Lung and Colorectal Cancer Cells to the BH-Mimetic ABT-737 in Hypoxia via Down Regulation of Mcl-1. Harrison L, Micha D, Brandenburg M, Morrow C, Simpson K, Makin G, Denenny O, Hodgkinson C, Blackhall F, Dive C Journal of Clinical Investigation, 121(3):1075-87 (2011)
Prognostic Significance and Molecular Characteristics of Circulating Tumour Cells and Circulating Tumour Microemboli in Patients with Small Cell Lung Cancer. Hou JM, Krebs M, Lancashire L, Sloane R, Backen A, Priest L, Greystoke A, Zhou C, Morris K, Ward T, Blackhall FH and Dive C. J Clin Oncol, (12):1556-63 (2011).
Circulating Tumor Cells as a Window on Metastasis Biology in Lung Cancer. Hou JM, Krebs M, Ward T, Sloane R, Priest L, Hughes A, Clack G, Ranson M, Blackhall FH and Dive C. Am J Path, i178:989-996 (2011).
Validation of an ELISA for the determination of rituximab pharmacokinetics in clinical trials subjects. Hampson G, Ward TH, Cummings J, Bayne M, Tutt AL, Cragg MS, Dive C, Illidge TM. J Immunol Methods. 31;360(1-2):30-8 (2010)
Src family kinase inhibitor saracatinib (AZD0530) impairs oxaliplatin uptake in colorectal cancer cells and blocks organic cation transporters. Morrow, C.J., Ghattas, M., Smith, C., Bönisch, H., Bryce, R.A., Hickinson, D.M., Green, T.P., Dive, C. Cancer Research. 70(14):5931-41 (2010)
Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer. Board RE, Wardley AM, Dixon JM, Armstrong AC, Howell S, Renshaw L, Donald E, Greystoke A, Ranson M, Hughes A, Dive C. Breast Cancer Res Treat. 120(2):461-7 (2010)
Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study. Board RE, Ellison G, Orr MC, Kemsley KR, McWalter G, Blockley LY, Dearden SP, Morris C, Ranson M, Cantarini MV, Dive C, Hughes A. Br J Cancer. 101(10):1724-30 (2009)
Evaluation of Circulating Tumor Cells and Serological Cell Death Biomarkers in Small Cell Lung Cancer Patients Undergoing Chemotherapy. Hou JM, Greystoke A, Lancashire L, Cummings J, Ward T, Williamson A, Board R, Amir E, Hughes S, Krebs M, Hughes A, Ranson M, Lorigan P, C Dive, Blackhall FH. American Journal of Pathology. 175(2):808-16 (2009)
Blocking PI3-Kinase Activity in Colorectal Cancer Cells Reduces Proliferation but does not Increase Apoptosis Alone or in Combination with Cytotoxic Drugs. Martin-Fernandez C., Bales J., Hodgkinson C., Welman A., Welham M. J., Dive C. and Morrow C. J. Molecular Cancer Research 7(6):955-65 (2009)
Phase I Trial of AEG35156 Administered as a 7-Day and 3-Day Continuous Intravenous Infusion in Patients With Advanced Refractory Cancer. Dean E, Jodrell D, Connolly K, Danson S, Jolivet J, Durkin J, Morris S, Jowle D, Ward T, Cummings J, Dickinson G, Aarons L, Lacasse E, Robson L, Dive C, Ranson M. J Clin Oncol. 27(10):1660-6. (2009)
Fit-for-purpose' validation of SearchLight multiplex ELISAs of angiogenesis for clinical trial use. Backen AC, Cummings J, Mitchell C, Jayson G, Ward TH, Dive C. J Immunol Methods. 342(1-2):106-14. (2009)
Quantitative multiplexed quantum dot immunohistochemistry Sweeney, E.,Ward, T. H.,Gray, N.,Womack, C.,Jayson, G.,Hughes, A., Dive, C.,Byers, R. Biochem Biophys Res Commun 374(2): 181-6. (2008)
Circulating biomarkers of cell death after treatment with the BH-3 mimetic ABT-737 in a preclinical model of small-cell lung cancer Micha, D.,Cummings, J.,Shoemaker, A.,Elmore, S.,Foster, K.,Greaves, M.,Ward, T.,Rosenberg, S.,Dive, C.,Simpson, K. Clin Cancer Res 14(22): 7304-10. (2008).
Preclinical evaluation of M30 and M65 ELISAs as biomarkers of drug induced tumor cell death and antitumor activity. Cummings, J.,Hodgkinson, C.,Odedra, R.,Sini, P.,Heaton, S. P.,Mundt, K. E.,Ward, T.,Wilkinson, R. W.,Growcott, J.,Hughes, A.,Dive, C. Mol Cancer Ther 7(3): 455-63. (2008).
Multiplexed assays for detection of mutations in PIK3CA. Board, R. E.,Thelwell, N. J.,Ravetto, P. F.,Little, S.,Ranson, M.,Dive, C.,Hughes, A.,Whitcombe, D. Clin Chem 54(4): 757-60. (2008).
Optimisation of circulating biomarkers of cell death for routine clinical use. Greystoke, A.,Cummings, J.,Ward, T.,Simpson, K.,Renehan, A.,Butt, F.,Moore, D.,Gietema, J.,Blackhall, F.,Ranson, M.,Hughes, A., Dive, C. Ann Oncol 19(5): 990-5. (2008).